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Abstract
Aim: To explore the physiological consequences of the ryanodine receptor
(RyR2)-P2328S mutation associated with catecholaminergic polymorphic
ventricular tachycardia (CPVT).
Methods: We generated heterozygotic (RyR2
p/s) and homozygotic (RyR2
s/s)
transgenic mice and studied Ca
2+ signals from regularly stimulated, Fluo-
3-loaded, cardiac myocytes. Results were compared with monophasic action
potentials (MAPs) in Langendorff-perfused hearts under both regular and
programmed electrical stimulation (PES).
Results: EvokedCa
2+transientsfromwild-type(WT),heterozygote(RyR2
p/s)
and homozygote (RyR2
s/s) myocytes had indistinguishable peak amplitudes
with RyR2
s/s showing subsidiary events. Adding 100 nm isoproterenol pro-
duced both ectopic peaks and subsidiary events in WT but not RyR2
p/s and
ectopic peaks and reduced amplitudes of evoked peaks in RyR2
s/s. Regularly
stimulated WT, RyR2
p/s and RyR2
s/s hearts showed indistinguishable MAP
durations and refractory periods. RyR2
p/s hearts showed non-sustained
ventricular tachycardias (nsVTs) only with PES. Both nsVTs and sustained
VTs (sVTs) occurred with regular stimuli and PES with isoproterenol treat-
ment. RyR2
s/s hearts showed higher incidences of nsVTs before but mainly
sVTs after introduction of isoproterenol with both regular stimuli and PES,
particularly at higher pacing frequencies. Additionally, intrinsically beating
RyR2
s/s showed extrasystolic events often followed by spontaneous sVT.
Conclusion: The RyR2-P2328S mutation results in marked alterations in
cellular Ca
2+ homeostasis and arrhythmogenic properties resembling CPVT
with greater effects in the homozygote than the heterozygote demonstrating
an important gene dosage effect.
Keywords cardiac action potentials, cardiac arrhythmogenesis, catechol-
aminergic polymorphic ventricular tachycardia, genetically modiﬁed mice,
ryanodine receptor, P2328S-RyR2.
Cardiac ryanodine receptors (RyR2s) are large tetra-
meric channels mediating Ca
2+-induced release of
intracellularly stored Ca
2+ (CICR) into the cytosol
following opening of voltage-dependent sarcolemmal
L-type Ca
2+ channels (LTCC) during action potentials
(Bers 2002, Wehrens et al. 2003, Kontula et al. 2005,
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2006). Each (565 kDa) RyR2 monomer is associated
with a range of accessory, potentially regulatory,
proteins. These include calmodulin (CaM), the
12.6 kDa protein FKBP12.6 (also known as calstabin
2), protein kinase A (PKA), protein phosphatase 1
and 2A (PP1 and PP2A), and calmodulin-dependent
protein kinase II (CaMKII) bound to its cytoplasmic
scaffold domain at the N-terminal region (Bers 2002).
It has been suggested that FKBP12.6 binding to RyR2
stabilizes the closed state of the channel during
diastole and promotes the coupling of RyR2 subunits
enabling channel opening during excitation contrac-
tion coupling (Yano et al. 2000, 2005a, Bers 2002,
Wehrens et al. 2004).
The gene encoding RyR2s has been implicated in
the autosomal dominant inherited condition, catechol-
aminergic polymorphic ventricular tachycardia
(CPVT), which is associated with presentations of
adrenergically (exercise)-induced bi-directional and
polymorphic ventricular tachycardia (VT) potentially
leading to sudden cardiac death (SCD) in the absence
of structural cardiac disease (Laitinen et al. 2001,
Priori et al. 2001, 2002, Wehrens & Marks 2003). It
has been suggested that an increased release of SR
Ca
2+ into the cytosol causes delayed diastolic after-
depolarizations (DADs) in the action potential leading
to triggered activity in common with ﬁndings in
digitalis-induced VT (Rosen & Danilo 1980, Leen-
hardt et al. 1995, Tunwell et al. 1996, Priori et al.
2001, Kummer et al. 2006). Thus recent reports have
similarly implicated alterations in SR calsequestrin in
such pathology (Chopra et al. 2007).
Two groups ﬁrst identiﬁed RyR2 mutations in
CPVT patients; neither reported structural cardiac
abnormalities or echocardiographic evidence of
cardiac failure (Laitinen et al. 2001, Priori et al.
2001). The ﬁrst reported four missense mutations of
which S2246L, R2427S and N4104K were sporadic
and R4497C was found in ﬁve clinically affected
mutant carriers. The second group demonstrated three
unrelated Finnish families carrying mutations in
P2328S, Q4201R and V4653F. Seventeen members
of the ﬁrst of these families carried the P2328S
mutation. Of these, 10 of the 12 studied showed
exercise-induced VT. Two of these P2328S carriers
were asymptomatic but showed abnormalities on
clinical testing. The carriers within the family showed
normal QTc intervals, and mortality rates as reﬂected
in Kaplan–Meier analyses of 30–33% by the age of
35 years in common with the Q4201R and V4653F
carriers.
Genetically modiﬁed murine hearts are increasingly
used as models of human cardiac disease (London,
2001). However, translation of results from isolated
murine hearts to the in vivo clinical setting must
consider differences between both (1) species as well
as (2) the electrophysiological assessment protocols
employed. Thus (1) despite similar anatomy and ﬁbre
organization, murine and human hearts are markedly
different in basal heart rate, heart size and ion
channel expression (Vaidya et al., 1999). Although
murine and human ventricular APs share a steep
upstroke reﬂecting rapid Na
+ channel gating (Guo
et al. 1999) and a strong inﬂuence of transient
outward repolarizing K
+ current (Ito) on AP recovery,
differences in repolarizing currents cause murine
ventricular APs to overshoot and fall sharply in
contrast to the pronounced plateau phase of the
human ventricular AP (Danik et al. 2002). (2) A
signiﬁcant proportion of the physiological assay tech-
niques examined isolated perfused as opposed to in
situ hearts for limited (h) rather than prolonged
(years) intervals. Nonetheless, at the very least,
murine hearts provide useful resemblances with hu-
man hearts the extent of which merits basic investi-
gation. Thus, they have successfully been used to
replicate arrhythmogenic properties associated with
Brugada (BrS) and LQT3 syndromes (Stokoe 2007a,b;
Thomas et al. 2007a,b). Similarly, a CPVT-like ar-
rrhythmogenesis has been observed under conditions
of adrenaline and/or caffeine perfusion in a recent
murine model with RyR2 modiﬁcations targeted
instead at the C-terminal luminal sites implicated in
store-overload-induced Ca
2+ release (SOICR) (Jiang
et al. 2004, 2005, Cerrone et al. 2005).
This article reports the generation of murine hearts
containing P2328S mutations in the central region
of the RyR2 gene close to the FKBP12.6 binding site,
and represents the ﬁrst time both heterozygotic (p/s)
and homozygotic (s/s) transgenic mice are compared
and studied. Previous studies in HEK293 cells had
associated the P2328S variant with altered FKBP12.6
binding following PKA phosphorylation (Lehnart
et al. 2004). This variant therefore directly comple-
ments genetically modiﬁed murine hearts with alter-
ations targeted at the C-terminal luminal sites thought
to be involved in SOICR (Jiang et al. 2004, 2005,
Cerrone et al. 2005). The present experiments exam-
ined the physiological consequences of both p/s
and s/s mutations not only through cytosolic Ca
2+
measurements in isolated cardiac myocytes but
also electrophysiological recordings in Langendorff-
perfused hearts, and the extent to which the intact
murine systems show arrhythmogenic properties. Our
experiments thus clariﬁed the physiological conse-
quence of the P2328S (p/s) and (s/s) mutation, and
deﬁned the extent to which results from physiological
studies demonstrate that this murine system resembled
the human phenotype.
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Generation of RyR2
P2328S knock-in mice
The targeting vector for homologous recombination
consisted of a 5.89 kb genomic DNA fragment span-
ning a region from intron 44 to intron 47 of the RyR2
genomic sequence. The 5¢ and 3¢ ﬂanks were ampliﬁed
from 129Sv/Ev genomic DNA by PCR with PfuTurbo
(Stratagene, Amsterdam, the Netherlands) using prim-
ers designed to the mouse genome reference sequence
ENSMUSG00000021313. The codon change leading to
the P2328S variant occurs in exon 45. The 5¢ ﬂank was
ampliﬁed using primers on either side on exon 45 to
produce a 965-bp fragment. The forward primer
contained an AvrII site which could be used to linearize
the ﬁnal targeting construct (5¢ﬂankror: GTAAAGAAT-
GAGACCTAGGATATAGTT; 5¢ ﬂankrev: GCTTAG-
CTAGCCTGAAAATACCTACA). The 3¢ ﬂank was a
4925-bp PCR product ampliﬁed to continue the geno-
mic homology from a NheI site at the 3¢ end of the
5¢ ﬂank. Both forward and reverse primers contained
NotI sites for cloning into the targeting construct.
(3¢ ﬂankfor: GCTAAGCGGCCGCAAAGAACACAGT
TCAGAAACCTAT; 3¢ﬂankrev: ATGGTAGCGGCC-
GCTACCTAATATCACAAACACA).
Both ﬂanks were cloned into pCR-BluntII-Topo (Invi-
trogen, Paisley, UK) and sequenced. Clones whose exon
sequence was 100% identical to that predicted by the
database were chosen to form the targeting construct.
Single base changes to intron sequence (compared to the
mouse genome sequence, C57Bl/6) were accepted if they
occurred in more than one clone. To introduce the
required mutation into the 5¢ ﬂank the Invitrogen
GeneTailor site-directed mutagenesis system was used.
The forward mutagenesis primer (GGTGAGGCTGCT
CATCCGGAGAtCtGAGTGCTT) changes the coding
sequence from proline (CCC) to serine (tCt) and intro-
duces a novel BglII site for screening for introduction of
the mutation. (reverse primer: TCTCCGGATGAGC
AGCCTCACCACAACATTT).Plasmidswhichhadbeen
correctly mutagenized were identiﬁed by sequencing and
digestion with BglII (pCR-RyR25¢P2328S).
To create the targeting construct, the 3¢ ﬂank was
cloned into the NotI site of pCR-RyR25¢P2328SDTA.
To reduce non-homologous recombination in the ES
cells the PGK promoter-driven Diptheria toxin-A chain
gene (from pKO3¢/DT-Anew, a kind gift of Dr Michael
Snaith) was introduced 3¢ of the 3¢ ﬂank. The loxP
ﬂanked thymidine kinase/neomycin selection cassette
(loxPtkneo) (from plasmid pNT4) was added between
the two ﬂanks to give the ﬁnal targeting construct, pCR-
RyR25¢P2328SloxPtkneo3¢DTA (Fig. 1a). The target-
ing construct was checked by sequencing and restriction
digestion at each stage of its construction.
Two electroporations of the linearized targeting
construct into 129Sv/Ev ES cells were performed from
which 132 ES clones were picked. After PCR screening
for correct homologous recombination of the 5¢ (Hot-
star Taq: Qiagen, West Sussex, UK) and 3¢ ﬂank (Long
Range Taq: Fermentas, York, UK) only one clone was
found to be positive. The primer positions for this
screening are indicated in Figure 1a. The PCR products
of each screen were cloned and sequenced to show that
there had been no sequence rearrangements and that the
only detectable sequence change was the desired intro-
duction of the codon change. This was conﬁrmed by
BglII digestion. The ES clone was karyotyped to conﬁrm
it had the correct number of chromosomes (40).
To remove the loxPtkneo selection cassette this clone
was electroporated with plasmid expressing Cre
Recombinase (pPGKnlsCreSV40polyA, a kind gift from
Dr Sam Aparicio) and selected in gancyclovir to
promote the loss of the loxPtkneo selection cassette.
Twelve colonies were picked and screened by PCR to
check for loss of the selection cassette (Primers RyR2f:
GGGGAGTTGGCTGCTGAGAA; RyR2r: CGGGCA-
CACACTCACCACCAA). The PCR product was
cloned and sequenced to conﬁrm that it contained the
expected RyR2 genomic sequence with 204 bp of
vector, including a single loxP site, introduced into
intron 45 at the NheI site at the end of the 5¢ ﬂank. The
karyotype of the new clone was reconﬁrmed and then
this clone was injected into C57Bl/6 blastocysts to
produce chimeras. Conﬁrmed germline transmitting
chimeras were mated to 129Sv/Ev females. The line
was then maintained as a mixture of RyR2
p/s heterozy-
gous matings or RyR2
s/s homozygous matings.
Reverse transcription PCR. Total RNA was isolated
from mouse ventricle or skeletal muscle using the
Qiagen RNeasy ﬁbrous tissue mini kit. The RNA was
quantiﬁed using a Nanodrop ND-1000 (NanoDrop
Technologies, Inc., Wilmington, DE, USA, supplied by
LabTech International, East Sussex, UK) and 0.5 lgo f
RNA was reverse transcribed using random primers and
AMV Reverse Transcriptase (both from Promega,
Southampton, UK) in the following reaction: RNA
was incubated at 70  C for 10 min, then placed on ice
and the following reagents added: 2 lL 0.1 m DTT,
4 lL5 · RT buffer, 1 lL1 0m m dNTPs, 1 lL lg
)1
Random primers, 0.5 lL RNAguard (Pharmacia, Sand-
wich, UK), 10 U AMV RT in a total volume of 10 lL.
The reaction mix was then incubated at 25  C for
10 min, 42  C for 60 min and 70  C for 15 min.
Control reactions in which the RT enzyme was replaced
with water were included to exclude ampliﬁcation from
genomic DNA. The resulting cDNA was then diluted to
50 mL and stored at )80  C. To set up the PCR
reaction 2 lL of cDNA was added to 0.5 lL1 0m m
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Figure 1 (a) RyR2 P2328S targeting construct (top to bottom; four panels). DNA fragment consisting of introns 44–48 of RyR2
gene (top panel) including the 5.89 kb genomic DNA fragment into which the 966 bp fragment was inserted (second panel). This
gave a modiﬁed 5¢ to 3¢ sequence in the embryonic stem (ES) cells (third panel) within the targeted allele (bottom panel). (b)
Plasmids correctly mutagenized identiﬁed by sequencing and digesting with BglII to conﬁrm 216, 524 and 740 bp fragments.
(c) PCR showing a single 694 bp product in WT, three (694, 256 and 438 bp) in RyR2
p/s and two (438 and 256 bp) products in
RyR2
s/s.
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)1
of each primer, 1 U SigmaRedTaq in a total volume of
25 lL. Cycling conditions for PCR: 94  C 2 min; then
30 repeats 93  C3 0s ,6 2 C3 0s ,7 2 C 60 s; followed
by 72  C for 10 min. Primers: RyR2 RT for,
GGCGAGTCCAAGGAAATCAC; RyR2 RTRev,
CCAGCATGAATCAAGTGCATTTC; mm b actin for,
GTTACCAACTGGGACGACATGG, mm b actin rev,
CCATACCCAAGAAGGAAGGCTG. The PCR prod-
ucts were digested by addition of BglII to the PCR mix
and incubation at 37  C for 2 h. The digest was
analysed by electrophoresis on a 2% agarose gel.
All mice used were originally supplied by Harlan
(Oxon, UK) and were housed at room temperature and
subjected to 12-h light/dark cycles. They were fed sterile
rodent chow and had free access to water at all times.
Mice used were wild-type (WT), heterozygote (RyR2
p/s)
and homozygote (RyR2
s/s) all aged between 3 and
6 months. Experimental mice were bred from a 129
genetic background, which, along with C57 mice, are
less susceptible to PES-induced arrhythmias than FBV
or Black Swiss animals (Maguire et al. 2003). All mice
used for subsequent experimental work were killed by
cervical dislocation [Schedule 1: UK Animal (Scientiﬁc
Procedures) Act 1986].
Measurements of cell [Ca
2+]
Single-cell experiments used mouse ventricular myo-
cytes isolated adapting an established enzymatic diges-
tion as described previously (Harding et al. 1992).
Following killing, hearts were excised rapidly and
cannulated before being connected to a Langendorff
perfusion system. The heart was then perfused for
1.5 min at 3 mL min
)1 with perfusion buffer containing
(mm), 120 NaCl, 5 MgSO4, 5.4 KCl, 5 sodium
pyruvate, 10 Hepes, 5 glucose, 20 taurine, 5 nitrilotri-
acetic acid (NTA; Sigma-Aldrich, Poole, UK), and
1–2 lm Ca
2+, pH 7.0 at 37  C. Subsequently the heart
was perfused for 25–28 min at 3 mL min
)1 with
digestion buffer containing (mm), 120 NaCl, 5 MgSO4,
5.4 KCl, 5 sodium pyruvate, 10 Hepes, 5 glucose, 20
taurine, to which was added collagenase type II (ﬁnal
concentration 1 mg mL
)1; Worthington Biochemical,
Lakewood, NJ, USA), hyaluronidase (ﬁnal concentra-
tion 1 mg mL
)1; Sigma-Aldrich) and 13 lm Ca
2+ and
set at pH 6.8 at a temperature of 37  C. The pale and
swollen heart was then removed and cut below the
atria. The digested tissue was teased gently with ﬁne
forceps and the dissociated cells were transferred to a
conical tube containing 12.5 mL digestion buffer with
50 mg bovine serum albumin (BSA) to inactivate
digestion. The resulting myocytes were subject to
further trituration using sterile plastic transfer pipettes,
and allowed to sediment by gravity for 10 min.
The cell suspension was then centrifuged for 1.5 min
at 200 rpm and the pellets re-suspended twice in wash
buffer containing (mm): 119 NaCl, 4.2 KCl, 0.94
MgSO4, 1.2 KH2PO4, 20 Hepes, 11.5 glucose, 20
taurine and 1 mg mL
)1 BSA, and bubbled with 95%
O2 +5 %C O 2, pH 7.4, to remove all traces of NTA,
collagenase and hyaluronidase. CaCl2 was then cau-
tiously re-introduced by stepwise additions of CaCl2 to
reach an approximate concentration of 1.25 mm by
centrifuging the preparation at each Ca
2+ reloading
stage to remove dead or swollen cells. During this
process, myocytes were examined periodically under the
microscope to conﬁrm a good yield of rod-shaped
myocytes (better than 60%) before continuing the
experiments. Cells were then transferred into a conical
tube (BD Biosciences, Oxford, UK) and incubated at
room temperature. The isolated myocytes were then
placed in a control Hepes-buffered Krebs-Henseleit
(KH) solution in a Perspex chamber 10 · 4 · 6.25 mm
(length · width · depth): the myocytes spontaneously
attached to the glass cover slip (4 · 4 cm, grade 1 cover
slip; (Merck, Herts, UK) forming the ﬂoor of the
chamber. The myocytes were stimulated to contract
using two in-built platinum ﬁeld electrodes running
the length of the chamber through which the periodic
ﬁeld stimulation was applied using a home-built square-
wave stimulator (R. Montgomery, Imperial College,
London, UK). This applied successive 40–60 V steps of
2.2 ms duration, immediately followed by a step of
similar duration and amplitude but opposite polarity
at a pacing frequency of 0.5 Hz.
During this stimulation cells were loaded with the
acetoxymethyl (AM) ester of the Ca
2+-sensitive dye
Fluo-3 (F-14242; Invitrogen, Paisley, UK; 50 lg vial
diluted in 30 lL pluronic to give a stock concentration
of 1.476 mm) by incubating the cells in a bath of
volume 500 lL containing KH buffer (with 1.25 mm
Ca
2+) with 2 lL of Fluo-3 AM solution for 15 min at
room temperature in the dark. The bath with the
myocytes was then transferred onto the stage of a Zeiss
LSM-510 laser scanning confocal microscope system
(Carl Zeiss, Welwyn Garden City, UK) with a ·20 air
objective (NA 0.5; confocal aperture 1000 lm, slice
thickness <42.4 lm) on a Zeiss Axiovert 100 M
inverted microscope. The ﬂuorescence (F) signals result-
ing from Ca
2+ binding to ﬂuo-3 were excited by a 488-
nm argon laser and detected between wavelengths of
505–550 nm. Images were analysed using an in-house
custom-written program. Series of 500 frames sampled
at 98 ms per frame (128 · 128 pixels per frame) were
used initially to monitor ﬂuorescence changes over time.
The appropriateness of the chosen frame capture rate
was corroborated in some experiments by conﬁrming
similar results following use of the faster line-scan mode
with a sampling rate of 960 ls per frame. Fluorescence
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of interest (ROI) placed at 7 lm intervals along the long
axis of each myocyte. Each ROI was circular, with an
area of 50 lm
2.C a
2+ transients obtained in response
to the regular pacing stimuli were quantiﬁed in terms of
their peak values that were normalized to the baseline
ﬂuorescence level F0, to give peak F/F0 values following
each response to each stimulus. All values were calcu-
lated from three ROIs for each myocyte and the mean
peak F/F0 values as well as the baseline diastolic values
were calculated. All traces had stable baselines con-
ﬁrming consistent laser intensities and detector gains.
The results were expressed as mean  SEM and com-
pared using anova (spss software, SPSS, Chicago, IL,
USA).
Whole heart electrophysiological experiments
The electrophysiological experiments on arrhythmo-
genesis at the whole heart level used a Langendorff-
perfused preparation adapted for the murine model
(Papadatos et al. 2002, Balasubramaniam et al. 2003).
The contracting heart was stimulated with platinum-
stimulating electrodes applied to the epicardial surface,
usually 15 min at 10 Hz, and was allowed to reach its
physiological steady state. The heart was paced from
its right ventricle at three times its threshold level
(between 3 and 5 V) using square-wave stimuli of
2 ms duration (Grass S48 stimulator; Grass Telefactor
(UK), Slough, UK). Monophasic action potentials
(MAPs) were recorded from the epicardial basal
surface of the left ventricle using a MAP electrode
(Linton Instruments, Harvard Apparatus, Edenbridge,
UK).
Hearts were subject to two stimulation protocols.
First, they were regularly paced at 6, 8, 10 and 12 Hz
for periods of up to 30 min to assess for tendencies to
spontaneous arrhythmogenesis. Secondly, programmed
electrical stimulation (PES) of the heart was then
carried out using a variation of an existing clinical
technique (Saumarez & Grace 2000, Saumarez et al.
2003). This applied stimulation sequences that each
consisted of a drive train of pacing stimuli (S1)
applied with a 200 ms cycle length with an extra
stimulus (S2) inserted every eighth beat. The coupling
interval (S1S2) was successively reduced by 1 ms with
each cycle until the ventricular effective refractory
period (VERP) was reached. The MAP signals were
ampliﬁed, ﬁltered (band-pass ﬁlter 30 Hz to 1 kHz;
Gould-Nicolet Technologies, Ilford, Essex, UK) and
digitized using an analog-to-digital converter (Model
1401plus; Cambridge Electronic Design, Cambridge,
UK).
The MAP signals were analysed with Spike II
software (Cambridge Electronic Design) and MAP
traces were selected according to previously docu-
mented criteria requiring stable baselines with rapid
upstrokes and consistent amplitudes. The action poten-
tial durations (APD) at 30, 50, 70 and 90% repolari-
zation (APD30, APD50, APD70 and APD90) were fully
identiﬁed and tabulated in Excel (Microsoft, Redmond,
WA, USA). Results were all expressed as mean  SEM
comparing different groups of experimental animals
using anova (spss software).
Isoproterenol was dissolved initially in distilled water
to make a stock of 1 mm and the ﬁnal drug concentra-
tion was achieved by dilution with the control KH
buffer. The stocks were stored at )20  C and made
fresh on the day of each experiment. These agents were
obtained from Sigma-Aldrich.
Results
RyR2
P2328S mice
The three injections of embryonic stem cells into C57B/
6 blastocysts resulted in a total of eight male chimeras.
Each of these males was mated with Ca 57Bl/6 and a
129Sv/Ev female. Three of the chimeras showed germ
line transmission of the knock-in allele, two produced
no litters and two produced litters but did not show
germ line transmission. Genotyping of pups was
performed using primers RyR2f and RyR2r (Fig. 1a).
These span the vector sequence left in intron 46. A
second PCR can be used to conﬁrm the presence of the
RyR2
P2328S allele. The reverse primer binds to vector
sequence left in intron 45 and the primers span the
introduced mutation to produce a 740-bp product
which can be cut by BglII to produce two, 524 and
216 bp, products (Fig. 1b). Pups were genotyped at
3–4 weeks of age. Results of genotyping 404 mice gave
98 WT, 189 RyR2
p/s and 117 RyR2
s/s. This is not
statistically different from the expected numbers of 101,
202 and 101. The oldest mice in the colony were
18 months of age. There has been no signiﬁcant
additional mortality of either RyR2
p/s or RyR2
s/s
compared with WT.
To check that both alleles produced mRNA, RT-PCR
was performed on total RNA isolated from mouse
ventricle tissue. Figure 1c shows the results of RT-PCR
after the product had been digested by BglII and the
digest run on a 2% agarose gel. For each genotype the
RT-PCR reaction was run in triplicate. RNA from WT
mice produced a single product at 694 bp. RNA from
the heterozygous RyR2
p/s mice produced three prod-
ucts, uncut WT allele and digested RyR2
P2328S allele.
RNA from the homozygous RyR2
s/s mice produced only
two products (438 and 256 bp) showing that the
RT-PCR product is derived from the RyR2
P2328S allele
only. The b-actin gene was ampliﬁed in all samples as a
128
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were also included as negative controls. No ampliﬁca-
tion was seen in these reactions from either the RyR2 or
b-actin primers (data not shown). To show that the
RyR2 primers were not amplifying from RyR1-derived
cDNA, skeletal muscle-derived cDNA was used as a
template. No ampliﬁcation from the RyR2 primers was
seen in these reactions, but the b-actin primers were able
to amplify the expected product from the same samples
(data not shown).
The presence of the P2328S allele alters Ca
2+
homeostasis
Differences in cellular Ca
2+ homeostasis that might
relate to the presence of the P2328S allele were ﬁrst
investigated through changes in the amplitude and
pattern of Ca
2+ transients in response to regular
stimulation (0.5 Hz) in isolated Fluo-3-AM loaded
WT (Fig. 2a,b), RyR2
p/s (Fig. 2c,d) and RyR2
s/s (Fig.
2e,f) myocytes. These were studied in KH buffer in both
the absence and presence of isoproterenol at a concen-
tration (100 mm) at which it would be possible to assess
the extent to which the RyR2
p/s or RyR2
s/s mutation
might either increase or decrease the incidence of
ectopic or subsidiary Ca
2+ events. In all three groups,
the traces showed stable baseline F/F0 and reproducible
responses to regular stimulation with minimal evidence
of ﬂuorophor bleaching over the sampling periods. Thus
the average values of the diastolic baseline F/F0 were
statistically indistinguishable (P >> 5%) between all
three groups whether in the presence and absence of
isoproterenol. Similar stability conditions applied to the
corresponding peak F/F0 amplitudes. We further quan-
tiﬁed the characteristics of such peak F/F0 (Table 1)
obtained from Ca
2+ transients of the kind illustrated in
Figure 2. In the absence of isoproterenol, Ca
2+ signals
observed immediately after the commencement of
stimulation in WT (Fig. 2a) and RyR2
p/s myocytes
(Fig. 2c) consisted of a series of responses each directly
following the individual stimuli. WT (Fig. 2a) and
RyR2
p/s myocytes (Fig. 2c) similarly did not show either
subsidiary events during the recovery time courses of the
evoked transients or spontaneous ectopic peaks in the
intervals between these regular responses to the imposed
stimuli. In contrast, the RyR2
s/s myocytes showed an
irregular pattern of responses that included subsidiary
events (4.65  1.46 events counted over a standard
sampling period of 50 s; n = 36 cells, three mice)
(Fig. 2e). After the addition of isoproterenol, WT
2 s 
(a)  (b) 
(c) (d) 
(e) (f) 
Figure 2 Ca
2+ peaks in regularly stimulated (0.5 Hz) Fluo-3-loaded WT (a, b), RyR2
p/s (c, d) and RyR2
s/s (e, f) before (a, c, e) and
following (b, d, f) introduction of 100 nm isoproterenol (Iso). Each trace depicts the initial 10 s obtained from a 50-s sequence
immediately following Fluo-3 loading.
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n = 6 cells, two mice) and subsidiary events
(9.00  1.34, n = 6 cells, two mice) (Fig. 2b), and
RyR2
s/s myocytes showed an increased incidence of
ectopic peaks (15.83  6.76) compared to the corre-
spondingly isoproterenol treated WT, but no subsidiary
events. RyR2
p/s myocytes showed neither ectopic peaks
nor subsidiary events (Fig. 2 and Table 1). In contrast,
Table 1 indicates that the peak F/F0 of Ca
2+ transients
directly evoked by each of the individual stimuli
were statistically indistinguishable on independently
weighted anova in WT, RyR2
p/s, RyR2
s/s regardless
of whether or not isoproterenol was present with the
exception of a reduced peak F/F0 in isoproterenol-
treated RyR2
s/s, as expected for a depletion of SR Ca
similarly produced by isoproterenol and caffeine (Vene-
tucci et al. 2007).
Further observations were made in cells following
continual stimulation extending over 10 min.
Resumption of scanning then conﬁrmed a similar
appearance of subsidiary events in RyR
s/s but not WT
or RyR2
p/s myocytes (Fig. 3a,c,e). Addition of isopro-
terenol then similarly resulted in the appearance of both
ectopic peaks and subsidiary events in WT (Fig. 3b) and
their continued absence in RyR2
p/s myocytes (Fig. 3d).
Such results agreed with the ﬁndings made immediately
following the onset of stimulation (Fig. 2) despite the
now reduced peak F/F0 values likely reﬂecting progres-
sive SR Ca
2+ depletion by such prolonged stimulation.
RyR2
s/s myocytes showed irregular patterns of release
events (Fig. 3f). These were further studied (Fig. 4)
under conditions of exposure to 0 (n = 7), 20 (n = 4),
50 (n = 4) and 100 nm (n = 5) isoproterenol respec-
tively: this gave progressive (and signiﬁcant) reductions
in peak F/F0 from 4.045  1.021 to 3.846  0.068
(n = 5), 1.63  0.0048 (n = 5) and 1.470  0.058
(n =5 ;P = 0.03 on independent weighted analysis), in
which a reduction in the frequency of subsidiary peaks
from 16.33  2.08 to 6.57  1.72 and 5.8  4.82,
following a series of 22 stimulations in 20 and 50 nm
isoproterenol, respectively, was replaced by the irregu-
lar pattern of release events at 100 nm isoproterenol
(Fig. 4d).
RyR2
s/s cells demonstrated Ca
2+ waves hitherto
associated with arrhythmogenic properties in caffeine-
treated murine myocytes (Balasubramaniam et al.
2005), following the addition of isoproterenol. As
described above, Ca
2+ signals, synchronized to the
applied stimuli, were observed in the presence of KH
buffer with 1.25 mm Ca
2+ for the WT and RyR2
p/s
myocytes before and following addition of 100 nm
isoproterenol. However, addition of 100 nm isoprote-
renol resulted in an appearance of propagated Ca
2+
waves along the longitudinal axis of the cell in the
RyR2
s/s (Fig. 5). The arrows highlight the path taken by
the Ca
2+ wave, starting from the upper end of the cell
and moving along its length. Similar results were
observed in n = 5 cells.
Action potentials from hearts containing the P2328S allele
during regular pacing
Experiments on isolated Langendorff-perfused whole
hearts compared electrophysiological properties of WT,
RyR2
p/s and RyR2
s/s hearts, exploring for arrhythmo-
genic tendency both before and following addition of
100 nm isoproterenol in each heart. Mice were aged
between 3 and 6 months (WT: one female, two males;
RyR2
p/s: four females, four males; and RyR2
s/s: one
female, six males). The experiments used both regular
pacing and PES procedures, which imposed an S2
extra stimulus following eight-beat (S1) conditioning
Table 1 Comparison of the characteristics of Ca
2+ signals in regularly stimulated WT, RyR2
p/s and RyR2
s/s cardiac myocytes
WT RyR2
p/s RyR2
s/s
Mean peak F/F0  SEM
Krebs buffer (n) 3.04  0.22 (6)
  3.15  0.06 (12)
  3.34  0.08 (36)
 ***
Isoproterenol (n) 2.88  0.25 (6)
  3.16  0.04 (12)
  1.59  0.10 (18)***
Mean numbers of ectopic peaks
Krebs buffer (n)0  0.0 (6)*** 0  0.0 (12) 0.79  0.56 (36)**
Isoproterenol (n) 8.00  2.99 (6)*** 0  0.0 (12) 15.83  6.76 (18)**
Mean numbers of evoked responses with subsidiary events
Krebs buffer (n)0  0.0 (6)*** 0  0.0 (12) 4.65  1.46 (36)*
Isoproterenol (n) 9.00  1.34 (6)*** 0  0.0 (12) 0  0.0 (18)*
WT, wild-type; RyR2
p/s, heterozygote; RyR2
s/s, homozygote.
Symbols indicate values subject to one-way anova of ﬁndings obtained between designated groups, or in each group before and
after introduction of isoproterenol with the following results:
 P = ns, *P < 0.05, **P < 0.01, ***P < 0.001.
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each stimulus cycle. Experiments used pacing (S1)
frequencies of 6, 8, 10 and 12 Hz respectively. WT,
RyR2
p/s and RyR2
s/s hearts paced at 10 Hz showed
statistically indistinguishable VERPs of 63  11.2
(n = 3), 56.3  8.4 (n = 3) and 66.5  18.5 ms (n =3
hearts) respectively.
The experiments ﬁrst examined MAP waveforms in
hearts regularly paced at 10 Hz for at least 30 min in
KH buffer before and after addition of isoproterenol.
They assessed for the presence or absence of changes
in APD of the kind reported for LQTS mice models
on recent occasions (Head et al., 2005; Stokoe
et al., 2007a,b; Thomas et al., 2007a,b). APD values
10 s
(a) (b)
(c) (d)
(e) (f)
Figure 3 Ca
2+ peaks in regularly stimulated (0.5 Hz) Fluo-3-loaded WT (a, b), RyR2
p/s (c, d) and RyR2
s/s (e, f) before (a, c, e) and
following (b, d, f) introduction of 100 nm isoproterenol (Iso). Each trace depicts a 50-s sequence obtained 10 min following
commencement of stimulation following Fluo-3 loading.
5 s 
(a) (b) 
(c) (d) 
Figure 4 Ca
2+ transients in regularly stimulated (0.5 Hz) Fluo-3-loaded RyR2
s/s myocytes before (a) and following introduction of
20 nm (b), 50 nm (c) and 100 nm (d) isoproterenol (Iso). Each trace was obtained from a 50-s sequence immediately following ﬂuo-
3 loading.
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70, 90) from regularly paced WT (n = 3 hearts),
RyR2
p/s (n = 7 hearts) and RyR2
s/s (n = 7 hearts)
before and 20 min after addition of isoproterenol
indicated uniform MAPs (Fig. 6ai,ii,b i,ii and ci,ii
respectively), with no signiﬁcant differences in all
these APD durations between WT (Fig. 6aiii), RyR2
p/s
(Fig. 6biii) and RyR2
s/s hearts (Fig. 6ciii). Such ﬁnd-
ings parallel reports on a previously described
R4496C mutant where QT intervals, of WT and the
mutant mice did not present signiﬁcant differences
whether before or after adrenergic stimulation (Cer-
rone et al. 2005). These data therefore parallel ﬁnd-
ings that CPVT carriers of the RyR2-P2328S
mutation (Paavola et al. 2007) showed increases in
endocardial MAP durations considerably smaller than
the clinical QTc prolongations thought to account for
the LQTS phenotype (Keating & Sanguinetti, 2001;
Scoote & Williams, 2002; Laurita & Katra, 2005;
Priori & Napolitano, 2005).
Arrhythmic properties of hearts containing the P2328S
allele during regular pacing and programmed electrical
stimulation at varying frequencies
The presence or absence of an arrhythmogenic pheno-
type was then investigated in the WT, RyR2
p/s and
RyR2
s/s hearts subject to both regular pacing and PES.
VT was identiﬁed as a series of regular electrical
deﬂections recurring at high frequencies independent
of any pacing spikes that were present. Arrhythmias
lasting >30 s were deﬁned as being sustained (sVT) and
those lasting <30 s as being non-sustained (nsVT). On
these criteria: (1) regularly paced WT hearts showed no
Figure 5 A series of confocal microscope images, obtained from complete galleries showing similar patterns, depicting typical Ca
2+
waves in a single ventricular RyR2
s/s myocyte loaded with Fluo-3 in the presence of Krebs-Henseleit buffer with 1.25 mm Ca
2+
following perfusion with 100 nm isoproterenol. The arrows highlight the path taken by a typical Ca
2+ wave.
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12 Hz) explored whether isoproterenol was present
(n = 3) or absent (n = 4 hearts) (data not shown). (2)
The RyR2
p/s hearts showed relatively few arrhythmo-
genic phenomena, when regularly paced, in the absence
of isoproterenol. Thus, of seven hearts, only one then
showed an episode of sVT at a pacing rate of 12 Hz.
However, addition of isoproterenol (100 nm) enhanced
arrhythmic tendency with 1, 1 and 0 episodes of nsVT
at pacing frequencies of 6, 8 and 10 Hz and 0, 1, 0 and
1 episodes of sVT at a pacing frequency of 6, 8, 10 and
12 Hz respectively (n = 5 hearts). (3) RyR2
s/s hearts
showed noticeably greater arrhythmic tendencies even
prior to addition of isoproterenol (Fig. 7). Two hearts
then showed episodes of nsVT at 8 and 10 Hz (Fig. 7b),
and two further hearts showed episodes of sVT at
10 Hz (n = 11 hearts). (4) Addition of isoproterenol
increased this arrhythmic tendency. Thus, its introduc-
tion resulted in (n = 5 hearts) 2, 1, 0 and 0 episodes of
sVT at pacing frequencies of 6, 8, 10 and 12 Hz
respectively. Finally, spontaneous after-depolarizations,
previously implicated in the triggering of arrhythmias,
were observed in hearts paced at both 8 and 10 Hz
(n = 2) (Fig. 7c).
The subsequent electrophysiological experiments
explored for arrhythmogenic substrate as reﬂected in
initiation of VT by extrasystolic (S2) stimulations
applied during PES procedures (Fig. 8). This gave
results that correlated well with the pacing studies.
They demonstrated that (5) WT hearts were not
arrhythmogenic at all pacing frequencies, whether
before (n = 4, Fig. 8a) or after (n = 3, Fig. 8b) intro-
duction of isoproterenol. In contrast, (6) both RyR2
p/s
and RyR2
s/s hearts showed an arrhythmogenicity
exacerbated by isoproterenol. Thus, ﬁve of seven
RyR2
p/s hearts (Fig. 8c) showed nsVT at all applied
pacing frequencies. Isoproterenol (100 nm) increased
this incidence in four of ﬁve hearts. The RyR2
s/s
hearts showed not only higher incidence of nsVT, but
also an occurrence of sVT (n = 11 hearts, Fig. 8e).
Addition of 100 nm isoproterenol resulted in full sVT
(n = 5) (Fig. 8f). Taken together, these results suggest
that the RyR2-P2328S mutation results in increased
tendencies to nsVT as well as sVT in mice. This is
WT 
i 
KH buffer
(a) 
(b) 
(c) 
ii 
100 nM Iso
iii 
RyR2p/s 
§ 
‡ 
RyR2s/s 
§ 
† 
‡ 
P = 0.58 
§P = 0.17 
†P = 0.54 
P = 0.15 
§P = 0.89 
†P = 0.40 
‡P = 0.23 
P = 0.06 
§P = 0.37 
†P = 0.29 
‡P = 0.82 
† 
§ 
† 
‡ 
100 ms 
Figure 6 Monophasic action potential waveforms of whole isolated perfused hearts from WT (a), RyR2
p/s (b) and RyR2
s/s (c),
before (i) and after (ii) the addition of 100 nm isoproterenol (Iso); (iii) quantiﬁes traces of this kind and plots action potential
duration (APD) values at 30, 50, 70, and 90%, APD30, 50, 70, 90. The results of the paired t-test for APD values obtained in the
absence and presence of isoproterenol in each genotype are shown. These did not show any signiﬁcant differences for all three
genotypes.
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RyR2 mutations (Swan et al. 1999, Laitinen et al.
2001, Priori et al. 2001, 2002).
RyR2
s/s hearts additionally show arrhythmic behaviour
during intrinsic activity
Spontaneous arrhythmogenic phenomena were only
observed in intrinsically paced RyR2
s/s and not in WT
(n =3 )o rRyR2
p/s (n = 7). Six of 11 RyR2
s/s hearts
showed early after depolarizations (EADs) that inter-
cepted the recovery phase of their preceding action
potentials (Fig. 9a), and 11 of 11 showed coupled beats
consisting of pairs of full action potentials (Fig. 9b).
There was one example of nsVT following the coupled
beats. When stimulation was ceased and re-introduced
at a pacing rate of 10 Hz, it resulted in an episode of
ventricular ﬁbrillation (Fig. 9c). These ﬁndings are
consistent with reports in which CPVT patients exhi-
bited episodes of polymorphic VT leading to SCD while
asleep or at rest (Allouis et al. 2005, d’Amati et al.
2005, Postma et al. 2005).
Discussion
Catecholaminergic polymorphic ventricular tachycardia
(CPVT) associated with SCD (Wehrens & Marks 2003,
Francis et al. 2005, George et al. 2007), has been linked
to mutations in the gene encoding the ryanodine
receptor (RyR2)-sarcoplasmic reticular Ca
2+ release
channel (Swan et al. 1999, Priori et al. 2001). The
mutations concerned are primarily clustered in three
regions of the gene namely, the N-terminal region (176–
433), central domain (2246–2504) and the C-terminal
region (4104–4653) (Wehrens & Marks 2003).
In contrast to murine models directed to the C and
N-terminal regions, there have been no such models
involving the important central region (Cerrone et al.
2005, Kannankeril et al. 2006). This study reports the
generation of mice with a knock-in mutation in the
nsVT 
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250 ms 
250 ms 
250 ms 
Figure 7 Monophasic action potential waveforms of whole isolated perfused hearts in Krebs-Henseleit buffer from RyR2
s/s (a). Of
the three groups studied, RyR2
s/s hearts showed the highest incidence of ventricular tachycardias (b) which could be either sustained
(>30 s) or non-sustained (<30 s) and early after depolarizations (EADs) (asterisks) (c). Results shown for hearts subject to regular
pacing at 8 Hz.
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was ﬁrst identiﬁed, in common with carriers for the
Q4201R and V4653F in three unrelated Finnish fam-
ilies. The P2328S mutation is located in the large central
cytoplasmic domain of RyR2, near the binding site of
the regulatory protein FKBP12.6 (George et al. 2007);
the Q4201R and V4653F mutations occur in the
carboxy-terminal region of the receptor associated with
the pore region (Tunwell et al. 1996). All the human
carriers showed mortality rates of 33% between the
ages of 10 and 35 years and threshold heart rates of
130 beats min
)1 for the triggering of ventricular
arrhythmogenesis during exercise despite an absence
of structural abnormalities or heart failure (Laitinen
et al. 2001). Recent clinical studies of carriers for the
P2328S, as well as the Q4201R and V4653F, mutations
reported runs of polymorphic tachycardia during exer-
cise with a mean age of onset of symptoms of
34  16 years. Furthermore, endocardial MAP record-
ings at the right ventricular septum from patients with
one of the three RyR2 mutations showed delayed
afterdepolarizations (DADs) in three of 15 CPVT
patients. These occasionally coincided with premature
ventricular complexes both before and during adrena-
line infusion that were never observed in control
subjects (Paavola et al. 2007).
There has been extensive discussion about the
association between mutations in the RyR2, including
that of P2328S, and the CPVT phenotypes, particu-
larly concerning possible roles of FKBP12.6-RyR2
binding (Brillantes et al., 1994; Masumiya et al. 2003,
Zissimopoulos & Lai 2005, Thomas et al. 2006).
Three RyR2 CPVT mutations (S2246L, R2474S and
R4497C) have been associated with low channel
activity in the absence of PKA at a wide range of
cytosolic [Ca
2+] and enhanced sensitivity to PKA
activation increasing open RyR2 probabilities (Weh-
rens et al. 2003). Similarly, investigations for arrhyth-
mic mechanisms following adrenergic stimulation in
HEK293 cells expressing P2328S (and Q4201R and
S2 
WT 
KH buffer + 10 Hz extra syst. stim. (a) 
(c) 
(e) 
(b) 
(d) 
(f) 
100 nM Iso + 10 Hz extra syst. stim.
S2 
S2  S2 
KH buffer + 10 Hz extra syst. stim. 100 nM Iso + 10 Hz extra syst. stim.
RyR2s/s 
RyR2p/s 
S2 
S2 
KH buffer + 10 Hz extra syst. stim. 100 nM Iso + 10 Hz extra syst. stim.
200 ms
200 ms
200 ms 200 ms 
200 ms 
200 ms 
Figure 8 Monophasic action potentials (APs) recorded from the epicardium of WT (a, b), RyR2
p/s (c, d) and RyR2
s/s hearts (e, f)
before (a, c, e) and after (b, d, f) the addition of 100 nm isoproterenol (Iso). All experiments were performed during programmed
electrical stimulation (PES) at 10 Hz; the arrows indicate S2 extra-stimuli. Of the events observed the examples illustrated of the
WT (a) and RyR2
p/s (c) isolated perfused hearts showed persistent regular rhythm with no arrhythmogenic events at 10 Hz during
the PES procedures. Five of seven RyR2
p/s hearts (1, 1, 2, 3 episodes at 8, 8, 10 and 12 Hz respectively) showed nsVT. In four of ﬁve
RyR2
p/s hearts studied in the presence of 100 nm isoproterenol, 0, 3, 3, and 1 hearts showed nsVT at pacing frequencies of 6, 8, 10
and 12 Hz, respectively, and one heart showed sVT both at 10 and 12 Hz. The RyR2
s/s hearts showed 3, 3, 3, and 5 episodes of
nsVT and 0, 1, 3 and 1 episodes of sVT at pacing rates of 6, 8, 10 and 12 Hz respectively (n = 11 hearts). Addition of 100 nm
isoproterenol (n = 5) resulted in a high incidence (2, 3, 3 and 4 episodes) of sVT. In the example shown, the S2 extra-stimuli
initiated an episode of non-sustained VT lasting for less that 30 s in KB buffer alone (e). Sustained VT lasting for more than 30 s was
often observed following addition of 100 nm isoproterenol in the same heart during PES at 10 Hz (f). Scale bar 200 ms.
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defect with leaky Ca
2+ release channels showing
signiﬁcant rightward shift in half-maximal inhibitory
Mg
2+ concentration and decreased FKBP12.6 binding
(Lehnart et al. 2004, Wehrens et al. 2004, Paavola
et al. 2007).
However, other studies have reported that mutations
in the RyR2 central region variously showed increased
(N2386I and Y2392C) and decreased (R2427S,
S2246L and P2328S) FKBP12.6 binding afﬁnity (Tiso
et al. 2002 and Wehrens et al. 2003 respectively),
although a decreased afﬁnity with C-terminal muta-
tions (Q4201R, R4496C and V4653F) (Wehrens et al.
2003). S2808D-myotubes did not show spontaneous
Ca
2+ oscillations at any concentration of FKBP12.6
(Goonasekera et al., 2005). Fluorescence resonance
energy transfer investigations of the functional impact
of C-terminal and central domain RyR2 mutations
suggested effects on RyR2 channel activity independent
of FKBP12.6 binding and PKA phosphorylation
(George et al., 2004 and reviewed in George et al.
2003, 2006, Jiang et al. 2004, Liu et al. 2006). Such
discrepancies led to alternative suggestions implicating
elevations of SR store Ca
2+ content to a threshold level
producing spontaneous SOICR with unaltered
FKBP12.6-RyR2 interaction in CPVT. SOICR occurred
in HEK293 cells expressing WT RyR2 exposed to
elevated extracellular [Ca
2+]0 (Diaz et al. 1997, Jiang
et al. 2004). It also occurred in cells expressing RyR2
containing the N4104K, R4496C and N4895D muta-
tions, as well as further RyR2 mutations from central
(S2246L and R2474S), C- (Q4201R and I4867M) and
N-terminal (R176Q (T2504M) and L433P) regions, in
the form of increased frequencies of Ca
2+ oscillations
and decreased SR Ca content. Single mutant RyR2
channels showed increased activation sensitivities with
a luminal Ca
2+ of 300 lm and increased basal [
3H]
ryanodine binding (see also Jiang et al. 2005). Such
ﬁndings were corroborated using the ﬁrst RyR2-
R4496C (+/)) knock-in mouse model equivalent to
the R4497C mutation identiﬁed in CPVT patients. Five
of 14 such mice showed either nsVT or sVT only with
exercise stress testing followed by adrenaline adminis-
tration. Four of eight of a second group developed
arrhythmias following adrenaline and caffeine admin-
istration, as did four of ﬁve pre-treated with K201
(Cerrone et al. 2005). Recent optical mapping studies
further characterized these arrhythmogenic character-
istics (Cerrone et al. 2007). Subsequent analyses dem-
onstrated that pacing protocols of increasing
frequencies induced DADs in RyR2-R4496C (+/))
cardiomyocytes but not in the WT. Superfusion with
isoproterenol induced both DADs and triggered activity
in the RyR2-R4496C (+/)) but not in the WT. Finally,
the heterozygote showed slightly increased RyR2-
FKBP12.6 interaction compared with WT that was
unchanged in the presence or absence of caffeine and
adrenaline (Liu et al. 2006).
Our data provide complementary mouse models
using the P2328S mutation, at a central site remote
from the luminal C-terminal, R4496C site. We have for
the ﬁrst time compared all three genotypes (WT, RyR2
p/s
200 ms
**
(a)
(b)
(c)
* sVT
VF
RyR2s/s
Figure 9 Monophasic action potentials (APs) recorded from the epicardium of intrinsically paced initially non-arrhythmogenic
RyR2
s/s hearts. Experiments were performed in the absence (a, b) and presence of electrical stimulation prior to (c). Of the
spontaneous events observed both (a): early-after depolarizations (EADs) (*) that produced episodes of sustained monomorphic VT
(sVT) when stimulation resumed, and (b): coupled beats (**) were observed in six of 11 hearts. (c) Persistent ventricular ﬁbrillation
(VF) occurring following the cessation of regular S1 pacing after two intrinsic MAPs.
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s/s) at both the single-cell and whole heart
level. The presence of P2328S allele appears to impart
an arrhythmogenic tendency, greater in both RyR2
p/s
and RyR2
s/s compared with WT. We report successively
greater effects on Ca
2+ transients, arrhythmogenicity,
the effect of b-adrenergic stimulation, and the presence
and absence of afterpotentials in the order
WT < RyR2
p/s < RyR2
s/s, adding important observa-
tions concerning the effects of gene dosage. Thus, there
was an increased amplitude of Ca
2+ transients evoked
by regular stimulation in isolated ventricular myocytes
with ectopic Ca
2+ peaks occurring speciﬁcally in the
RyR2
s/s myocytes as was observed following adminis-
tration of isoproterenol to the WT. Isoproterenol
reduced such transients in RyR2
s/s, suggesting Ca
2+
store depletion and an appearance of propagated Ca
2+
waves associated with arrhythmogenic tendencies on
earlier occasions (Venetucci et al. 2007). In contrast,
MAPs from isolated Langendorff-perfused WT, RyR2
p/s
and RyR2
s/s hearts had similar waveforms and refrac-
tory periods, whether in the presence or absence of
isoproterenol. Nevertheless, both regular pacing
through a range of frequencies and extrasystolic stimuli
demonstrated a progressively increasing tendency to the
development of non-sustained, then sustained,
arrhythmogenesis, in isolated, Langendorff-perfused
RyR2
p/s and RyR2
s/s but not WT hearts. These effects
were more marked at higher pacing frequencies and in
the RyR2
s/s hearts. The latter showed the greatest
arrhythmogenic tendency as well as extrasystolic events
often followed by spontaneous sustained VT even
during intrinsic beating. In addition to establishing an
arrhythmogenic phenotype, and associating this with
altered Ca
2+ homeostasis, these data therefore associ-
ated a physiological CPVT phenotype with the clinically
described P2328S mutation, in the cytoplasmic central
region of the RyR2.
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Supporting information
Additional supporting information may be found in the
online version of this article.
We provide two sets of sequential images from isolated,
Fluo-3-loaded myocytes as supplementary data that (1)
provide further conﬁrmation for the series of still images
of propagating waves are shown in Fig. 5 that were
obtained from RyR2
s/s myocytes following treatment
with isoproterenol and (2) distinguish them from the
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2+ transients as obtained from F/F0 values obtained
over ﬁxed regions of interest, that were obtained from
WT myocytes (Fig. 2b). These were made using frame
captures of ﬂuorescence (F) signals resulting from Ca
2+
binding to ﬂuo-3 excited by a 488-nm argon laser and
detected between wavelengths of 505–550 nm sampled
at 98 ms/frame (128 · 128 pixels/frame). The appro-
priateness of the chosen frame capture rate was
corroborated in some experiments by conﬁrming similar
results following use of the faster line-scan mode with a
sampling rate of 960 ls/frame. The ﬁrst series of images
are from unstimulated RyR2
s/s myocyte studied in the
presence of isoproterenol. It illustrates a propagating
increase of local Ca
2+ ﬂuorescence running along the
cells concerned. This is in contrast to the second series
of images from a regularly stimulated WT myocyte in
which the evoked Ca
2+ is synchronized over the whole
cell surface.
Video Clip S1. (1)
Video Clip S2. (2)
Please note: Wiley-Blackwell are not responsible for the
content or functionality of any supporting materials
supplied by the authors. Any queries (other than missing
material) should be directed to the corresponding
author for the article.
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